Featured Publications
Efficacy of covid-19 vaccines in immunocompromised patients: systematic review and meta-analysis
Lee A, Wong S, Chai L, Lee S, Lee M, Muthiah M, Tay S, Teo C, Tan B, Chan Y, Sundar R, Soon Y. Efficacy of covid-19 vaccines in immunocompromised patients: systematic review and meta-analysis. The BMJ 2022, 376: e068632. PMID: 35236664, PMCID: PMC8889026, DOI: 10.1136/bmj-2021-068632.Peer-Reviewed Original ResearchConceptsImmune mediated inflammatory disorderOrgan transplant recipientsEfficacy of COVID-19 vaccinesTransplant recipientsRisk of biasImmunocompromised patientsSolid cancersInflammatory disordersImmunocompetent controlsHaematological cancersSeroconversion ratesMeta-analysisCOVID-19 vaccineMRNA vaccinesVaccine doseSystematic reviewCOVID-19 mRNA vaccinesWHO International Clinical Trials Registry PlatformCentral Register of Controlled TrialsVaccine non-respondersAssociated with seroconversionInternational Clinical Trials Registry PlatformProspective observational studyRegister of Controlled TrialsLow risk of bias
2023
COVID-19 Severity and Waning Immunity After up to 4 mRNA Vaccine Doses in 73 608 Patients With Cancer and 621 475 Matched Controls in Singapore
Tan W, Tan J, Lim J, Tan R, Bin Lee A, Leong F, Lee S, Chai L, Tan T, Bin Abdul Malek M, Ong B, Lye D, Chiew C, Chng W, Lim S, Bharwani L, Tan I, Sundar R, Tan K. COVID-19 Severity and Waning Immunity After up to 4 mRNA Vaccine Doses in 73 608 Patients With Cancer and 621 475 Matched Controls in Singapore. JAMA Oncology 2023, 9: 1221-1229. PMID: 37440245, PMCID: PMC10346511, DOI: 10.1001/jamaoncol.2023.2271.Peer-Reviewed Original ResearchConceptsIncidence rate ratiosCancer survivorsVaccine doseSevere diseaseCohort studyTreated patientsProspective multicenter observational cohort studyCompeting-risk regression analysisMulticenter observational cohort studyMatched controlsVaccine efficacyVaccine effectivenessRisk of poor outcomesWaning of vaccine effectivenessSevere COVID-19 disease outcomesMRNA vaccine doseRisk of deathObservational cohort studyMRNA-based vaccinesSocioeconomic statusSARS-CoV-2 DeltaRate ratiosCOVID-19 hospitalizationIncidence rateOmicron waveClinical efficacy and long-term immunogenicity of an early triple dose regimen of SARS-CoV-2 mRNA vaccination in cancer patients.
Lee M, Peng S, Lee A, Wong S, Tay R, Li J, Tariq A, Goh C, Tan Y, Tan B, Teo C, Chan E, Ooi M, Chng W, Chee C, Ho C, Walsh R, Wong M, Su Y, Alexander L, Sethi S, Tan S, Chan Y, Tan K, Lee S, Chai L, Sundar R. Clinical efficacy and long-term immunogenicity of an early triple dose regimen of SARS-CoV-2 mRNA vaccination in cancer patients. Annals, Academy Of Medicine, Singapore 2023, 52: 8-16. PMID: 36730801, DOI: 10.47102/annals-acadmedsg.2022302.Peer-Reviewed Original ResearchConceptsSARS-CoV-2 mRNA vaccinesDoses of SARS-CoV-2 mRNA vaccinesMRNA vaccinesCancer patientsThird doseHaematological malignanciesLong-term immunogenicityCompared to patientsRisk of severe diseaseAnti-neoplastic treatmentActive cancer therapyVirus neutralisation assaySARS-CoV-2 infectionSystemic chemotherapyNo patientEarly administrationSeroconversion ratesVaccine immunogenicitySolid tumorsClinical efficacyClinical outcomesSevere infectionsCancer therapyHumoral responseActive treatment
2022
Booster doses of COVID-19 vaccines for patients with haematological and solid cancer: a systematic review and individual patient data meta-analysis
Mai A, Lee A, Tay R, Shapiro L, Thakkar A, Halmos B, Grinshpun A, Herishanu Y, Benjamini O, Tadmor T, Shroff R, LaFleur B, Bhattacharya D, Peng S, Tey J, Lee S, Chai L, Soon Y, Sundar R, Lee M. Booster doses of COVID-19 vaccines for patients with haematological and solid cancer: a systematic review and individual patient data meta-analysis. European Journal Of Cancer 2022, 172: 65-75. PMID: 35753213, PMCID: PMC9163022, DOI: 10.1016/j.ejca.2022.05.029.Peer-Reviewed Original ResearchConceptsIndividual patient data meta-analysisPatient data meta-analysisSolid cancersBooster doseNon-respondersData meta-analysisHaematological cancersMeta-analysisAntibody titresBooster dose of COVID-19 vaccineAssociated with increased durationIncreased risk of severe diseaseResponse to booster vaccinationAge of patientsRisk of severe diseaseVaccine non-respondersDose of COVID-19 vaccineSystematic reviewJoanna Briggs Institute Critical Appraisal ChecklistGastrointestinal cancer patientsCOVID-19 vaccine booster doseReduced vaccine immunogenicityVaccine booster doseImproved seroconversionCritical Appraisal Checklist